Prediction of Response to Tumor Necrosis Value-alpha Blocker Is Suggested by F-18-NaF SUVmax But Not by Quantitative Pharmacokinetic Analysis in Patients With Ankylosing Spondylitis
Prediction of response to tumor necrosis value-α blocker is suggested by 18F-NaF SUVmax but not by quantitative pharmacokinetic analysis in patients with ankylosing spondylitis
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q1
- 저널
- AMERICAN JOURNAL OF ROENTGENOLOGY214(6) · pp.1352 · 2020
- 피인용
- Web of Science 10Scopus 11
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 3.013
- ISSN
- 0361-803X
저자
- 김근영제1저자Department of Nuclear Medicine, BioMedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
- 손승민Department of Orthopaedic Surgery, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
- 고태식Department of Orthopaedic Surgery, BioMedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
- 박경준Department of Nuclear Medicine, BioMedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
- 김인주Department of Nuclear Medicine, BioMedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
- 이정섭Department of Orthopaedic Surgery, BioMedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
- 김성장교신저자Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.
초록
OBJECTIVE. We aimed to evaluate the pharmacokinetics and maximum standardized uptake value (SUVmax) of F-18-NaF PET/CT for assessment of disease activity and prediction of response in patients with ankylosing spondylitis (AS). MATERIALS AND METHODS. Twenty-seven patients (age, interquartile range, 30.25-49.75 years) with AS who were receiving a tumor necrosis factor-alpha (TNF-alpha) blocker were included. All patients underwent dynamic PET of the pelvis followed by whole-body PET/CT. Quantitative analysis of kinetic data of the sacroiliac joints (SIJs) was performed, and the SUVmax of the SIJs and SUVmax of the spine were calculated. Clinical indexes related to AS disease activity (serum C-reactive protein level, Bath ankylosing spondylitis disease activity index [BASDAI], and Bath ankylosing spondylitis functional index) were evaluated. Clinical response was defined as an improvement from the initial BASDAI score of 50% or more (BASDAI 50) within 2 years after baseline F-18-NaF PET/CT. RESULTS. The BASDAI score at F-18-NaF PET/CT was significantly different between the responders and nonresponders: F-18-NaF uptake at the spine was significantly higher in the responders than in the nonresponders. Only SUVmax of the spine had a significant positive correlation with BASDAI score at PET/CT (r = 0.38, p = 0.048). The BASDAI score at PET/CT (odds ratio [OR], 35.32; 95% CI, 2.09-57.84; p = 0.014) and SUVmax of the spine (OR, 1469; 95% CI, 0.79-27.27; p = 0.027) were significantly associated with BASDAI 50 response prediction. CONCLUSION. The results of our study suggest that the SUVmax of the spine on whole-body F-18-NaF PET/CT is a reliable and noninvasive biomarker for predicting therapeutic response to TNF-alpha blocker and shows better performance for predicting response than quantitative pharmacokinetic parameters. Fluorine-18-labeled NaF PET/CT showed axial bone lesions with bone formation and can be used as a monitoring tool in patients with AS receiving anti-TNF-alpha drugs. However, these results need to be validated in a larger cohort.
키워드
ankylosing spondylitisPETsacroiliac jointsodium fluorideF-18-FLUORIDE PET/CTBONE-FORMATIONDOUBLE-BLINDEFFICACYF-18-FDGDISEASESAFETYSCINTIGRAPHYBIOMARKERBREAST
식별자
- Scopus EID
- 2-s2.0-85085264076
- WoS UID
- 000536126600020



로그인
연구물 목록으로